Contract ZooMAb® antibody development services are the solution for generating antibodies for your desired targets to meet your research and production needs. This service takes advantage of extensive expertise in immunogen design and preparation, antibody development and screening, application-specific testing, and antibody manufacturing at the scale that is relevant to your goals.
Unlike conventional monoclonal and polyclonal technologies, ZooMAb® recombinant antibodies are developed from a proprietary B cell immortalization and recombinant expression platform using tissue culture-based methods. These stable immortalized cell lines provide extensive clonal selection and preserve immunization diversity. In contrast, other recombinant antibody development methods require immediate cloning to ensure clone viability, limiting the number of clones for further screening which results in the loss of highly specific candidates and creates the need for reimmunization.
The antibodies developed using our award-winning innovative technology exhibit lot-to-lot consistency, reproducibility, and application performance with the option to formulate the final buffer presentation for your specific downstream applications. With expert technical support, our contract ZooMAb® antibody development service offers excellent success rates and is scalable for your needs.
To continue reading please sign in or create an account.Don't Have An Account?